Biogen Pulls Application for Alzheimer's Drug in Europe

Biogen said on Friday it will withdraw the marketing application for its controversial Alzheimer's drug, aducanumab, in Europe after the US biotech company failed to convince the European regulator of the treatment's benefits.
Reuters Health Information

source https://www.medscape.com/viewarticle/972612?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?